Arcutis Biotherapeutics Inc
ARQT
Company Profile
Business description
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Contact
3027 Townsgate Road
Suite 300
Westlake VillageCA91361
USAT: +1 805 418-5006
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
342
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.30 | 12.80 | -0.14% |
| CAC 40 | 7,635.03 | 13.99 | 0.18% |
| DAX 40 | 23,924.36 | 78.29 | 0.33% |
| Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
| FTSE 100 | 9,164.31 | 21.58 | 0.24% |
| HKSE | 25,051.16 | 140.53 | 0.56% |
| NASDAQ | 21,169.42 | 252.87 | 1.21% |
| Nikkei 225 | 41,032.65 | 237.79 | 0.58% |
| NZX 50 Index | 12,887.10 | 6.94 | 0.05% |
| S&P 500 | 6,345.06 | 45.87 | 0.73% |
| S&P/ASX 200 | 8,828.10 | 15.60 | -0.18% |
| SSE Composite Index | 3,640.55 | 6.56 | 0.18% |